Vimarsana
Biggest News Aggregation in the World

Page 42 - Scientific Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scientific Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scientific Program Today - Breaking & Trending Today

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Published: June 3, 2021

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Source: investegate.co.uk
Related Topics:
United StatesIsabella ZinckSamir ShahJulie MasowThomas HungerbuehlerSloan SimpsonRachel LevineNuclear Medicine Through InnovationVirtual Scientific ProgramNovartis CompanyElsevier IncNovartis External CommunicationsExchange CommissionNational Cancer Institute SurveillanceNational Research CouncilInstitute Of MedicineNational AcademiesScientific ProgramNational Cancer InstituteEnd ResultsAdvanced Accelerator ApplicationsPrescribing InformationAccelerator ApplicationsPositron Emission TomographySingle Photon Emission Computed Tomography
Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma - Vimarsana News

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Published: June 2, 2021

/PRNewswire/ -- Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients...

Source: prnewswire.com
Related Topics:
United StatesJulie MasowJamie BennettStephenj SchusterSloan SimpsonStefan HendriksAmerican Society Of Clinical OncologyVirtual Scientific ProgramLymphoma ProgramPerelman School Of MedicineAbramson Cancer CenterExchange CommissionUniversity Of Pennsylvania PennNj Novartis Pharmaceuticals CorporationUniversity Of PennsylvaniaResearch In Penn Perelman School Of MedicineAmerican SocietyClinical OncologyVirtual Scientific MeetingMargarita Louis Dreyfus ProfessorChronic Lymphocytic LeukemiaLymphoma Clinical CarePerelman SchoolAbramson CancerLee Scale
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Published: June 2, 2021

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Source: investegate.co.uk
Related Topics:
United StatesSan AntonioComunidad Autonoma De CatalunaIsabella ZinckThomas HungerbuehlerSusanne SchaffertDennisj SlamonAshley BufordJeana SachsSamir ShahJulie MasowSloan SimpsonNovartis KisqaliUniversity Of CaliforniaClinical Translational ResearchAmerican Society Of Clinical OncologyEuropean Society Of Medical OncologyNovartis External CommunicationsAmerican Cancer SocietyVirtual Scientific ProgramNovartis Institutes For Biomedical ResearchAstex PharmaceuticalsDrug AdministrationEuropean CommissionNovartis Oncology Communications
Novartis Pharma AG: Novartis Kisqali reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients - Vimarsana News

Novartis Pharma AG: Novartis Kisqali reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Published: June 2, 2021

MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS benefit

Source: finanznachrichten.de
Related Topics:
United StatesSan AntonioComunidad Autonoma De CatalunaIsabella ZinckThomas HungerbuehlerSusanne SchaffertDennisj SlamonAshley BufordJeana SachsSamir ShahJulie MasowSloan SimpsonNovartis KisqaliUniversity Of CaliforniaClinical Translational ResearchAmerican Society Of Clinical OncologyEuropean Society Of Medical OncologyNovartis External CommunicationsAmerican Cancer SocietyVirtual Scientific ProgramNovartis Institutes For Biomedical ResearchAstex PharmaceuticalsDrug AdministrationEuropean CommissionNovartis Oncology Communications
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Published: June 2, 2021

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Source: investegate.co.uk
Related Topics:
United StatesIsabella ZinckThomas HungerbuehlerStephenj SchusterSamir ShahJulie MasowSloan SimpsonStefan HendriksNovartis KymriahFiona PhillipsAmerican Society Of Clinical OncologyVirtual Scientific ProgramLymphoma ProgramNovartis Oncology CommunicationsPerelman School Of MedicineAbramson Cancer CenterNovartis Us External CommunicationsNovartis External CommunicationsExchange CommissionUniversity Of Pennsylvania PennResearch In Penn Perelman School Of MedicineUniversity Of PennsylvaniaAmerican SocietyClinical OncologyVirtual Scientific Meeting